Regenerative Medicine · South Florida
The Future of Healing
Exosome therapy leverages the body's natural cellular communication pathways to potentially support tissue repair, reduce inflammation, and promote regeneration — guided by neurosurgical precision.
Patient Selection
Is This Right for You?
Exosome therapy may be considered as part of a comprehensive treatment plan for patients with certain degenerative, inflammatory, or pain-related conditions. Every patient is unique — candidacy is determined through individualized evaluation.
- Individuals seeking alternatives to invasive surgical procedures who have not responded adequately to conservative management
- Patients with degenerative disc disease, facet arthropathy, or other spinal degenerative conditions contributing to chronic pain
- Those with joint degeneration, chronic tendon or ligament injuries, or osteoarthritis of the knee, shoulder, or hip
- Patients interested in therapies that aim to support the body's natural repair mechanisms rather than merely masking symptoms
- Individuals who understand that results vary and that exosome therapy is an emerging field with evolving evidence
What to Expect
The procedure is performed in an outpatient setting and typically takes less than one hour. Most patients experience mild soreness at the injection site for 24–48 hours.
Your specific post-procedure instructions — including medication restrictions and activity modifications — will be provided in detail during your visit and at the time of treatment.
Tissue regeneration is a gradual biological process. While some patients report improvement within weeks, the full therapeutic window extends over 3–9 months.
Informed Consent: All patients complete a comprehensive informed consent process prior to any procedure, including written acknowledgment of the investigational nature of exosome therapy, a detailed discussion of risks, benefits, alternatives, and the current FDA regulatory status.
Payment: Exosome therapy is not covered by most insurance plans or Medicare/Medicaid. Patients are responsible for full payment. Call (954) 633-7858 for pricing and payment options.
The Process
From Consultation to Recovery
Evaluation
Comprehensive neurosurgical consultation to review your medical history, imaging, and clinical presentation. We determine whether exosome therapy may be appropriate for your specific condition.
Treatment Plan
A personalized protocol is developed, including injection site mapping, dosing considerations, and expected timelines. All available options — conservative, interventional, and surgical — are discussed transparently.
Administration
Exosomes are delivered via targeted injection to the affected area under image guidance when indicated. The outpatient procedure typically takes under an hour, with minimal discomfort and no general anesthesia.
Follow-Up
Re-evaluation at approximately 6 weeks post-procedure to assess progress. Tissue repair is gradual, with optimal results often observed over 3–9 months. Additional treatments may be indicated.
The Novo Difference
Why Choose a Neurosurgeon
for Regenerative Therapy
Anatomical Expertise
Board-certified neurosurgical training provides an unparalleled understanding of spinal anatomy, neural pathways, and the intricate structures surrounding injection targets — precision that defines safer, more effective delivery.
Diagnostic Rigor
Before any regenerative intervention, we perform a thorough workup to establish an accurate diagnosis. Exosome therapy is only considered when it aligns with clinical evidence and your individual pathology.
Evidence-Based Practice
Our approach is grounded in the current scientific literature. We are transparent about what the research shows, where uncertainty remains, and what outcomes are realistic — not promised.
Andreas C. Tomac, MD, PhD, FAANS
Dr. Tomac brings a truly distinctive expertise to regenerative medicine, combining board-certified neurosurgical excellence with over two decades of pioneering research in stem cell biology and neuroregeneration.
He earned his MD from the University of Rochester School of Medicine in New York and his PhD in Molecular Neurosciences from the Karolinska Institute in Stockholm — the institution that awards the Nobel Prize in Physiology or Medicine. He subsequently completed extended research fellowships at the National Institutes of Health (NIH) focused on stem cell targeting and therapies, and has published extensively in world-leading journals including Nature and Proceedings of the National Academy of Sciences (PNAS).
His foundational work on GDNF family ligands and neurotrophic factor pathways — critical to neuroprotection, neural regeneration, and dopaminergic neuron survival — represents the type of basic science that underpins today's regenerative medicine advances. Few neurosurgeons in the United States possess this depth of academic achievement in stem cell and molecular neuroscience research alongside active, high-volume clinical practice.
Understanding Exosomes
Cellular Messengers With
Regenerative Potential
Exosomes are nanoscale extracellular vesicles — typically 30 to 150 nanometers in diameter — naturally released by virtually every cell in the body. Once considered cellular waste, they are now understood as essential mediators of intercellular communication, carrying bioactive cargo including growth factors, cytokines, proteins, lipids, and genetic material (mRNA, microRNA) from cell to cell.
In the context of regenerative medicine, exosomes derived from mesenchymal stem cells (MSCs) are of particular interest. Preclinical and early clinical studies suggest these vesicles may modulate immune responses, reduce chronic inflammation, and support tissue repair — without the complexities of live cell transplantation. Unlike stem cells, exosomes do not replicate, do not contain DNA, and present a lower immunogenic profile than live cell transplantation.
Their mechanism of action involves direct cell-to-cell signaling: exosomes fuse with target cells and release their bioactive contents, instructing cells to initiate repair cascades, regulate inflammatory pathways, and restore homeostatic function. Research has demonstrated potential applications across orthopedics, neurology, wound healing, and pain management.
Product Integrity & Sourcing
We source our exosome products exclusively from GMP-compliant, FDA-registered facilities that produce isolated MSC exosomes from perinatal mesenchymal stem cell cultures using chemically defined, xeno-free media — not from direct processing of donor tissues. Products are manufactured in ISO 7 clean rooms with ISO 5 isolation hoods.
Every product lot undergoes multi-modality characterization including protein analysis (ELISA), RNA sequencing, NanoSight Nano Tracking Analysis, and advanced imaging verification with STORM super-resolution fluorescence microscopy — confirming the MSC origin and purity of each batch. Documented testing for sterility, endotoxin, and potency is completed prior to clinical use.
Begin the Conversation
Ready to Learn More?
Schedule a consultation with our neurosurgical team to explore whether regenerative therapy may be appropriate for your condition. No obligation — just an honest, evidence-based conversation.
Important Medical & Legal Disclosures
Last reviewed and updated: February 2026
Exosome therapy is not approved by the U.S. Food and Drug Administration (FDA) for the treatment, cure, or prevention of any disease or medical condition. No exosome product has received FDA approval for clinical use in the United States as of the date shown above. The FDA considers exosome products intended for therapeutic use to be unapproved biologics. The information presented on this page is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
The scientific evidence regarding exosome therapy is based on preclinical research and early-phase clinical studies. Results vary by individual and are not guaranteed. Potential risks include, but are not limited to: infection, bleeding, localized pain, nerve inflammation, allergic or immune-mediated reactions, and worsening of the treated condition. In patients with active or occult malignancy, there is a theoretical concern regarding tumor promotion from bioactive growth factors. Product composition may vary between batches, manufacturers, and source tissues. All treatment options, risks, benefits, and alternatives — including conservative management and surgical intervention — will be discussed in detail during your consultation.
Nothing on this page should be interpreted as a claim that exosome therapy is a cure, definitive treatment, or replacement for standard medical care. This therapy is offered as an investigational option and patients are encouraged to discuss all available treatment pathways with their treating physician. Florida Senate Bill 1768 (effective July 1, 2025) addresses stem cell therapies and does not directly authorize or regulate exosome products.
† Based on characterization of properly manufactured MSC-derived exosome products. Product composition is verified per lot through documented quality control testing.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW.
This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider and to research any therapy before undergoing treatment.